Topics

FDA declines to approve Acer Therapeutics' rare genetic disorder treatment

11:51 EDT 25 Jun 2019 | Reuters

Acer Therapeutics Inc said on Tuesday its treatment for a severe, rare genetic disorder that can cause blood vessels to fatally rupture was declined approval from the U.S. Food and Drug Administration.

Original Article: FDA declines to approve Acer Therapeutics' rare genetic disorder treatment

NEXT ARTICLE

More From BioPortfolio on "FDA declines to approve Acer Therapeutics' rare genetic disorder treatment"

Quick Search